PATENT CLAIM ANALYSIS

Application Number: 15777141
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "329000"]

Abstract:
This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH).

Claim (Index 2):
The method of  claim 1 , wherein the neovascularization is corneal, retinal, choroidal, uveal, or iris neovascularization.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 93.0
- Lexical Diversity: 2.71698
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14758724', '15684251', '12063653', '11330033', '13993317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7715107608858218
- 35 USC 102 Novelty (BERT): 0.6441979201440511
- Combined Prediction Score: 0.7587794768116447
- Mean Citation Score: 411.445188
- Max Citation Score: 626.72363
- Similarity Product: 554.4365828935241

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test